Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to -$1.5 billion.

  • Takeda Pharmaceutical's Cash from Investing Activities fell 9641.73% to -$1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.2 billion, marking a year-over-year increase of 1888.87%. This contributed to the annual value of -$2.4 billion for FY2025, which is 2508.28% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its Cash from Investing Activities stood at -$1.5 billion for Q4 2025, which was down 9641.73% from -$326.7 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Cash from Investing Activities registered a high of $2.8 billion during Q1 2021, and its lowest value of -$3.3 billion during Q1 2023.
  • Its 5-year average for Cash from Investing Activities is -$565.6 million, with a median of -$461.6 million in 2023.
  • Over the last 5 years, Takeda Pharmaceutical's Cash from Investing Activities had its largest YoY gain of 82531.8% in 2021, and its largest YoY loss of 1055469.47% in 2021.
  • Takeda Pharmaceutical's Cash from Investing Activities (Quarter) stood at -$608.2 million in 2021, then skyrocketed by 45.66% to -$330.5 million in 2022, then tumbled by 54.08% to -$509.2 million in 2023, then crashed by 49.27% to -$760.1 million in 2024, then plummeted by 96.42% to -$1.5 billion in 2025.
  • Its Cash from Investing Activities was -$1.5 billion in Q4 2025, compared to -$326.7 million in Q3 2025 and -$229.4 million in Q2 2025.